LXEO Lexeo Therapeutics, Inc.

Nasdaq www.lexeotx.com


$ 9.60 $ 0.81 (9.24 %)    

Friday, 17-Oct-2025 19:50:40 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 9.58
$ 9.13
$ 8.35 x 50
$ 9.95 x 110
$ 8.50 - $ 9.59
$ 1.45 - $ 11.72
4,079,946
na
517.33M
$ 2.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-24-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-11-2024 12-31-2023 10-K
8 12-11-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 guggenheim-initiates-coverage-on-lexeo-therapeutics-with-buy-rating-announces-price-target-of-30

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and announc...

 chardan-capital-maintains-buy-on-lexeo-therapeutics-raises-price-target-to-17

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and raises the price target fr...

 lexeo-therapeutics-fda-feedback-opens-faster-path-pivotal-study-for-friedreich-ataxia-gene-therapy-could-shrink-and-speed-up-approval

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for ...

 fda-outlines-process-to-speed-up-rare-disease-therapy-approvals

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

 hc-wainwright--co-maintains-buy-on-lexeo-therapeutics-lowers-price-target-to-9

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the pric...

 lexeo-therapeutics-q2-eps-060-beats-068-estimate

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(...

 oppenheimer-initiates-coverage-on-lexeo-therapeutics-with-outperform-rating-announces-price-target-of-20

Oppenheimer analyst Leland Gershell initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform rating and anno...

 the-fda-grants-breakthrough-therapy-designation-to-lexeo-therapeutics-lx2006-based-on-clinical-evidence-generated-on-both-cardiac-and-neurologic-measures-of-friedreich-ataxia

LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot ...

 1-lexeo-launches-40m-rna-heart-drug-venture-with-backing-from-top-biotech-investors

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for ...

 jp-morgan-maintains-overweight-on-lexeo-therapeutics-lowers-price-target-to-10

JP Morgan analyst Tessa Romero maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and lowers the price target from...

 hc-wainwright--co-maintains-buy-on-lexeo-therapeutics-lowers-price-target-to-15

HC Wainwright & Co. analyst Mitchell Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION